Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK)
HKD 0.67
(0.0%)
HKD 0.67
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 6.39 Billion CNY | -1.57% |
| 2022 | 6.5 Billion CNY | 21.61% |
| 2021 | 5.34 Billion CNY | 72.7% |
| 2020 | 3.09 Billion CNY | 17.72% |
| 2019 | 2.62 Billion CNY | -1.49% |
| 2018 | 2.66 Billion CNY | 18.32% |
| 2017 | 2.25 Billion CNY | 85.43% |
| 2016 | 1.21 Billion CNY | 7.72% |
| 2015 | 1.12 Billion CNY | -41.09% |
| 2014 | 1.91 Billion CNY | -4.81% |
| 2013 | 2.01 Billion CNY | -11.37% |
| 2012 | 2.27 Billion CNY | 22.15% |
| 2011 | 1.86 Billion CNY | 665.74% |
| 2010 | 242.92 Million CNY | -2.54% |
| 2009 | 249.25 Million CNY | 70.5% |
| 2008 | 146.19 Million CNY | 38.26% |
| 2007 | 105.73 Million CNY | 121.29% |
| 2006 | 47.78 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 6.43 Billion CNY | 0.0% |
| 2023 FY | 6.39 Billion CNY | -1.57% |
| 2023 Q4 | 6.39 Billion CNY | 0.0% |
| 2023 Q2 | 6.52 Billion CNY | 0.0% |
| 2022 FY | 6.5 Billion CNY | 21.61% |
| 2022 Q2 | 6.3 Billion CNY | 0.0% |
| 2022 Q4 | 6.5 Billion CNY | 0.0% |
| 2021 FY | 5.34 Billion CNY | 72.7% |
| 2021 Q2 | 3.62 Billion CNY | 0.0% |
| 2021 Q4 | 5.34 Billion CNY | 0.0% |
| 2020 Q4 | 3.09 Billion CNY | 0.0% |
| 2020 Q2 | 4.17 Billion CNY | 0.0% |
| 2020 FY | 3.09 Billion CNY | 17.72% |
| 2019 FY | 2.62 Billion CNY | -1.49% |
| 2019 Q2 | 3.03 Billion CNY | 0.0% |
| 2019 Q4 | 2.62 Billion CNY | 0.0% |
| 2018 Q4 | 2.66 Billion CNY | 0.0% |
| 2018 Q2 | 2.69 Billion CNY | 0.0% |
| 2018 FY | 2.66 Billion CNY | 18.32% |
| 2017 Q4 | 2.25 Billion CNY | 0.0% |
| 2017 FY | 2.25 Billion CNY | 85.43% |
| 2017 Q2 | 2.81 Billion CNY | 0.0% |
| 2016 Q2 | 1.66 Billion CNY | 0.0% |
| 2016 Q4 | 1.21 Billion CNY | 0.0% |
| 2016 FY | 1.21 Billion CNY | 7.72% |
| 2015 Q4 | 1.12 Billion CNY | 0.0% |
| 2015 Q2 | 1.51 Billion CNY | 0.0% |
| 2015 FY | 1.12 Billion CNY | -41.09% |
| 2014 Q2 | 1.7 Billion CNY | 0.0% |
| 2014 Q4 | 1.91 Billion CNY | 0.0% |
| 2014 FY | 1.91 Billion CNY | -4.81% |
| 2013 Q2 | 1.88 Billion CNY | 0.0% |
| 2013 Q4 | 2.01 Billion CNY | 0.0% |
| 2013 FY | 2.01 Billion CNY | -11.37% |
| 2012 FY | 2.27 Billion CNY | 22.15% |
| 2012 Q4 | 2.27 Billion CNY | 0.0% |
| 2012 Q2 | 1.81 Billion CNY | 0.0% |
| 2011 Q4 | 1.86 Billion CNY | 0.0% |
| 2011 FY | 1.86 Billion CNY | 665.74% |
| 2011 Q2 | 1.92 Billion CNY | 0.0% |
| 2010 FY | 242.92 Million CNY | -2.54% |
| 2010 Q4 | 242.92 Million CNY | 0.0% |
| 2009 FY | 249.25 Million CNY | 70.5% |
| 2008 FY | 146.19 Million CNY | 38.26% |
| 2007 FY | 105.73 Million CNY | 121.29% |
| 2006 FY | 47.78 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 142.28 Million HKD | -4396.989% |
| Grand Pharmaceutical Group Limited | 7.24 Billion HKD | 11.683% |
| Extrawell Pharmaceutical Holdings Limited | 170.4 Million HKD | -3654.779% |
| Wai Yuen Tong Medicine Holdings Limited | 709.65 Million HKD | -801.623% |
| Qianhai Health Holdings Limited | 94 Million HKD | -6706.598% |
| Lee's Pharmaceutical Holdings Limited | 930.06 Million HKD | -587.95% |
| Essex Bio-Technology Limited | 903.78 Million HKD | -607.96% |
| Tongfang Kontafarma Holdings Limited | 665.38 Million HKD | -861.604% |
| PuraPharm Corporation Limited | 689.65 Million HKD | -827.774% |
| SSY Group Limited | 4.49 Billion HKD | -42.379% |
| JBM (Healthcare) Limited | 366.75 Million HKD | -1644.609% |
| Jacobson Pharma Corporation Limited | 1.09 Billion HKD | -486.744% |
| China Resources Pharmaceutical Group Limited | 168.46 Billion HKD | 96.202% |